Paper Review Records
全部论文审稿周期
15 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
117
天
Type 2 diabetes prevention across the life course
作者
Yiying Wang; Jennifer L. Sargent; Chantal Mathieu; Elsa Vazquez-Arreola; Leigh Perreault; Ruth J. F. Loos; Lee-Ling Lim; Leontine Sandforth; Robert L. Hanson; Stephanie Kullmann; Julia Sbierski-Kind; Sara Y. Brucker; Martin Hrabé de Angelis; Fabian Theiss; Andrea Icks; Damon Mohebbi; Norbert Stefan; Viswanathan Mohan; Tiange Wang; Hubert Preissl; Michael Bergman; Jaakko Tuomilehto; Marie-France Hivert; Paul W. Franks; Andreas L. Birkenfeld展开收起
作者单位
1. Department of Internal Medicine IV—Diabetology, Endocrinology, Nephrology, University Hospital Tübingen, University of Tübingen, Tübingen, Germany; 2. Institute for Diabetes Research and Metabolic Diseases, Helmholtz Munich, Tübingen, Germany; 3. German Center for Diabetes Research, Neuherberg, Germany; 4. School of Public Health, Imperial College London, London, UK; 5. Heidelberg Institute of Global Health, University of Heidelberg, Heidelberg, Germany; 6. Department of Endocrinology, UZ Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium; 7. National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, USA; 8. Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, USA; 9. Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 10. The Charles Bronfman Institute for Personalized Medicine, Department of AI in Health, Icahn School of Medicine at Mount Sinai, New York, USA; 11. Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia; 12. The M3 Research Center, University Hospital Tübingen, University of Tübingen, Tübingen, Germany; 13. Department of Women’s Health, University Hospital Tübingen, University of Tübingen, Tübingen, Germany; 14. Institute of Experimental Genetics, Helmholtz Zentrum München, German Research Center for Environmental Health (GmbH), Neuherberg, Germany; 15. Chair of Experimental Genetics, TUM School of Life Sciences, Technische Universität München, Freising, Germany; 16. Helmholtz Munich, Munich, Germany; 17. Institute for Health Services Research and Health Economics, German Diabetes Center, Leibniz Center for Diabetes Research, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; 18. Institute for Health Services Research and Health Economics, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; 19. Institute of General Practice, Centre for Health and Society, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Düsseldorf, Düsseldorf, Germany; 20. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK; 21. Madras Diabetes Research Foundation (Indian Council of Medical Research Collaborating Centre of Excellence)–Dr. Mohan’s Diabetes Specialties Centre (International Diabetes Federation Centre of Excellence in Diabetes Care), Chennai, India; 22. National Clinical Research Center for Endocrine and Metabolic Diseases (Shanghai), Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; 23. NYU Grossman School of Medicine, Department of Medicine, Holman Division of Endocrinology, Diabetes and Metabolism, New York, USA; 24. Department of Public Health, University of Helsinki, Helsinki, Finland; 25. Department of Population Medicine at Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, USA; 26. Diabetes Unit, Massachusetts General Hospital, Boston, USA; 27. Genetic & Molecular Epidemiology Unit, Lund University Diabetes Centre, Department of Clinical Sciences, Lund University, Helsingborg, Sweden; 28. Precision Healthcare University Research Institute, Queen Mary University of London, London, UK; 29. Diabetes and Obesity Theme, School of Cardiovascular and Metabolic Medicine and Sciences, Faculty of Life Sciences and Medicine, King’s College London, London, UK展开收起
388
天
Divergent impacts of explainable AI for dermatological diagnosis on clinicians versus lay people
作者
Xuhai ‘Orson’ Xu; Haoyu Hu; Haoran Zhang; Will Ke Wang; Reina Wang; Luis R. Soenksen; Omar Badri; Sheharbano Jafry; Elise Burger; Lotanna Nwandu; Apoorva Mehta; Erik P. Duhaime; Asif Qasim; Hause Lin; Janis Karleen Pereira; Jonathan Hershon; Paulius Mui; Alejandro A. Gru; Noémie Elhadad; Lena Mamykina; Matthew Groh; Philipp Tschandl; Roxana Daneshjou; Marzyeh Ghassemi展开收起
作者单位
1. Columbia University, New York, USA; 2. Cornell University, Ithaca, USA; 3. Massachusetts Institute of Technology, Cambridge, USA; 4. Johns Hopkins University, Baltimore, USA; 5. Northeast Dermatology Associates, Beverly, USA; 6. Stanford University, Stanford, USA; 7. University of Utah, Salt Lake City, USA; 8. OSF HealthCare, Peoria, USA; 9. Centaur.AI, Boston, USA; 10. MedShr, London, UK; 11. Pathway, Montréal, Canada; 12. X=Primary Care, Cambridge, USA; 13. Northwestern University, Evanston, USA; 14. Medical University of Vienna, Vienna, Austria展开收起
103
天
The next generation of antibody–drug conjugates
作者
F. Mosele; A. Peltier; Y. Ozaki; A. Detappe; J. C. Soria; F. André展开收起
作者单位
1. Drug Development Department (DITEP), Gustave Roussy, Villejuif, France; 2. IHU PRISM National PRecISion Medicine Center in Oncology, Gustave Roussy, Villejuif, France; 3. INSERM U981, Gustave Roussy, Paris, France; 4. Department of Breast Medical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; 5. Université Paris-Saclay, Gustave Roussy, Inserm U1363, Biothérapies Innovantes, Villejuif, France; 6. Institut Strauss, Strasbourg, France; 7. Equipe Labellisée Ligue Contre le Cancer, Paris, France; 8. Strasbourg Drug Discovery and Development Institute (IMS), Strasbourg, France; 9. Université Paris-Saclay, Gif-Sur-Yvette, France; 10. Amgen, R&D, Global Oncology Development, Thousand Oaks, USA; 11. Department of Medical Oncology, Gustave Roussy, Villejuif, France展开收起
252
天
The genetic architecture of fibromyalgia across 2.5 million individuals
作者
Isabel Kerrebijn; Gyda Bjornsdottir; Keon Arbabi; Lea Urpa; Hele Haapaniemi; Gudmar Thorleifsson; Lilja Stefansdottir; Stephan Frangakis; Jesse Valliere; Lovemore Kunorozva; Erik Abner; Caleb Ji; Markus Kangur; Bitten Aagaard; Henning Bliddal; Søren Brunak; Mie T. Bruun; Maria Didriksen; Christian Erikstrup; Sarah Finer; Arni J. Geirsson; Daniel F. Gudbjartsson; Thomas F. Hansen; David van Heel; Ingileif Jonsdottir; Stacey Knight; Kirk U. Knowlton; Christina Mikkelsen; Lincoln D. Nadauld; Thorunn A. Olafsdottir; Sisse R. Ostrowski; Ole B. V. Pedersen; Saedis Saevarsdottir; Astros T. Skuladottir; Erik Sørensen; Hreinn Stefansson; Patrick Sulem; Olafur A. Sveinsson; Gudny E. Thorlacius; Unnur Thorsteinsdottir; Henrik Ullum; Arnor Vikingsson; Thomas M. Werge; Richa Saxena; Kari Stefansson; Chad M. Brummett; Bente Glintborg; Daniel J. Clauw; Thorgeir E. Thorgeirsson; Frances M. K. Williams; Nasa Sinnott-Armstrong; Hanna M. Ollila; Michael Wainberg展开收起
作者单位
1. Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada; 2. Institute of Medical Science, University of Toronto, Toronto, Canada; 3. Amgen deCODE Genetics, Reykjavik, Iceland; 4. Krembil Centre for Neuroinformatics, Centre for Addiction and Mental Health, Toronto, Canada; 5. Stanley Center for Psychiatric Research, Broad Institute, Cambridge, USA; 6. Center for Genomic Medicine, Massachusetts General Hospital, Boston, USA; 7. Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland; 8. Department of Anesthesiology, University of Michigan Medical School, Ann Arbor, USA; 9. Molecular and Population Genetics Program, Broad Institute, Cambridge, USA; 10. Division of Sleep and Circadian Disorders, Brigham and Women’s Hospital, Boston, USA; 11. Institute of Genomics, Estonian Genome Center, University of Tartu, Tartu, Estonia; 12. Department of Computer Science, University of Toronto, Toronto, Canada; 13. Department of Clinical Immunology, Aalborg University Hospital, Aalborg, Denmark; 14. The Parker Institute, Copenhagen University Hospital Bispebjerg Frederiksberg, Copenhagen, Denmark; 15. Department of Public Health, University of Copenhagen, Copenhagen, Denmark; 16. Novo Nordisk Center for Protein Research, University of Copenhagen, Copenhagen, Denmark; 17. Clinical Immunology Research Unit, Department of Clinical Immunology, Odense University Hospital, Odense, Denmark; 18. Department of Clinical Immunology, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark; 19. Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark; 20. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; 21. Wolfson Institute of Population Health, Queen Mary University of London, London, UK; 22. Department of Rheumatology, Landspitali University Hospital, Reykjavik, Iceland; 23. Neurogenomics, Translational Research Centre, Copenhagen University Hospital, Glostrup, Denmark; 24. Danish Multiple Sclerosis Center, Copenhagen University Hospital, Glostrup, Denmark; 25. Danish Headache Center, Copenhagen University Hospital, Glostrup, Denmark; 26. Blizard Institute, Queen Mary University of London, London, UK; 27. Precision Healthcare University Research Institute, Queen Mary University of London, London, UK; 28. Intermountain Medical Center, Intermountain Heart Institute, Salt Lake City, USA; 29. Intermountain Healthcare, Saint George, USA; 30. School of Health Sciences, Faculty of Medicine, University of Iceland, Reykjavik, Iceland; 31. Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 32. Department of Clinical Immunology, Zealand University Hospital, Koege, Denmark; 33. Department of Neurology, Landspitali University Hospital, Reykjavik, Iceland; 34. Statens Serum Institut, Copenhagen, Denmark; 35. Institute of Biological Psychiatry, Mental Health Services, Copenhagen University Hospital, Copenhagen, Denmark; 36. Department of Anesthesiology, Mass General Brigham, Harvard Medical School, Boston, USA; 37. Opioid Research Institute, Office for the Vice President for Research, University of Michigan, Ann Arbor, USA; 38. Overdose Prevention Engagement Network, Institute for Healthcare Policy and Innovation, Michigan Medicine, Ann Arbor, USA; 39. Copenhagen Center for Arthritis Research (COPECARE) and DANBIO, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark; 40. Chronic Pain and Fatigue Research Center, Department of Anesthesiology, University of Michigan, Ann Arbor, USA; 41. Department of Twin Research and Genetic Epidemiology, School of Life Course Sciences, King’s College London, London, UK; 42. Herbold Computational Biology Program, Fred Hutchinson Cancer Center, Seattle, USA; 43. Department of Genome Sciences, University of Washington, Seattle, USA; 44. Brotman Baty Institute, University of Washington, Seattle, USA; 45. Center for Synthetic Biology, University of Washington, Seattle, USA; 46. Center for One Health Research, University of Washington, Seattle, USA; 47. Department of Psychiatry, University of Toronto, Toronto, Canada; 48. Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada展开收起
257
天
Integrated care pathway in individuals with Long COVID: STIMULATE-ICP, a cluster-randomized, phase 3 trial
作者
STIMULATE-ICP Consortium展开收起
作者单位
1. University College London, London, UK; 2. Lancashire Clinical Trials Unit, University of Lancashire, Preston, UK; 3. The Francis Crick Institute, London, UK; 4. University College London Hospitals NHS Trust, London, UK; 5. Tameside and Glossop Integrated Care NHS Foundation Trust, Tameside General Hospital, Lancashire, UK; 6. Royal Free NHS Foundation Trust, London, UK; 7. Sheffield Teaching Hospitals NHS Foundation Trust, Northern General Hospital, Sheffield, UK; 8. Perspectum Ltd, Oxford, UK; 9. Applied Health Research Hub, University of Lancashire, Preston, UK; 10. Patient and Public Representative, C/O Institute of Health Informatics, University College London, London, UK; 11. Hull University Teaching Hospitals NHS Foundation Trust, Hull Royal Infirmary, Hull, UK; 12. Derbyshire Community Health Services NHS Foundation Trust, Ash Green Learning Disability Centre, Chesterfield, UK; 13. Living With Ltd, Brighton, UK; 14. Department of Health Sciences, University of York, York, UK; 15. University of Liverpool, Liverpool, UK; 16. University of Exeter, Exeter, UK; 17. Reading Central Primary Care Network, Pembroke Surgery, Reading, UK; 18. University of Southampton, Southampton, UK; 19. University Hospitals Sussex NHS Foundation Trust, Worthing Hospital, Worthing, UK; 20. Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK; 21. NHS England, London, UK; 22. Livewell Southwest, Plymouth, UK; 23. Department for Work and Pensions, London, UK; 24. Barts Health NHS Trust, The Royal London Hospital, London, UK; 25. NHS Highlands, Inverness, UK; 26. University of Leicester, Leicester, UK; 27. The Princess Alexandra Hospital NHS Trust, Harlow, UK; 28. University Hospitals of Leicester NHS Trust, Leicester Royal Infirmary, Leicester, UK; 29. University of Sussex, Brighton, UK; 30. University of Hull, Kingston upon Hull, UK; 31. Long Covid SOS, Aldridge, UK; 32. Department of Economics, The University of Auckland, Auckland, New Zealand; 33. Vauxhall Primary Care, Liverpool, UK; 34. Royal Devon and Exeter NHS Foundation Trust, Royal Devon and Exeter Hospital (Wonford), Exeter, UK展开收起
306
天
Maternal 6-valent group B Streptococcus vaccine in non-pregnant and pregnant females: a randomized phase 1/2 trial
作者
Shabir A. Madhi; Hasra Snaggs; Zahra Skogeby; Ye Feng; Shaun Barnabas; Jeffrey Baker; Lee Fairlie; Johannes Beeslaar; David Radley; Han-Qing Jiang; Natalie C. Silmon de Monerri; Raphael Simon; Lindsay McLaughlin; Michelle Gaylord; Julie Skinner; Iona Munjal; Annaliesa S. Anderson; Alejandra Gurtman展开收起
作者单位
1. South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 2. Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa; 3. Pfizer Vaccines, Pfizer Inc., Pearl River, USA; 4. Pfizer Vaccines, Pfizer Ltd, Marlow, UK; 5. Family Center for Research with Ubuntu, Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa; 6. Clinical Research Prime, Idaho Falls, USA; 7. Wits RHI, Faculty of Health Sciences, University of Witwatersrand, Johannesburg, South Africa; 8. Pfizer Vaccines, Pfizer Inc., Collegeville, USA展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天